CONCURRENT CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND DIABETES MELLITUS TYPE 2

Download full text PDF
Issue: 
11
Year: 
2017

Professor L. Sorokina, MD; Professor V. Mineev, MD; A. Pavlova; M. Nyoma, Candidate of Medical Sciences; V. Ivanov; Professor V. Trofimov, MD Acad. I.P. Pavlov First Saint Petersburg State Medical University

Chronic obstructive pulmonary disease is often associated with diabetes mellitus type 2. According to the literature, systemic inflammation is most frequently considered as a possible common pathogenetic component.
Keywords: 
pulmonology
endocrinology
chronic obstructive pulmonary disease
diabetes mellitus type 2
cytokines

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2016.
  2. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should) // Proc. Am. Thorac. Soc. – 2007; 4 (7): 522–5.
  3. Glaser S., Kruger S., Merkel M. et al. Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature // Respiration. – 2015; 89 (3): 253–64.
  4. Aparna A. Pulmonary Function Tests in Type 2 Diabetics and Non-Diabetic People - A Comparative Study // J. Clin. Diagnostic Research. – 2013; 7 (8): 1606–8.
  5. Romashov B.B., Chernov A.V., Poljakova N.V. Hronicheskaja obstruktivnaja bolezn' legkih na fone sostojanija insulinorezistentnosti // Molodoj uchenyj. – 2015; 14 (94): 80–4.
  6. Clini E., Crisafulli E., Radaeli A., et al. COPD and the metabolic syndrome: an intriguing assosiation // Int. Emerg. Med. – 2013; 8 (4): 283–9.
  7. Barnes P. Mediators of Chronic Obstructive Pulmonary Disease // Pharmacol. Rev. – 2004; 56 (4): 517–48.
  8. Adela R., Banerjee S. Role of inflammatory mediators in diabetes and cardiovascular diseases // Int. J. Sci. Technol. Manag. – 2015; 4 (01): 62–70.
  9. Spranger J., Kroke A., Mohlig M. et al. Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study // Diabetes. – 2003; 52: 812–7.
  10. Cazzola M., Matera M. IL-17 in chronic obstructive pulmonary disease // Exp. Rev. Respir. Med. – 2012; 6 (2): 135–8.
  11. Chen H., Ren X., Liao N. et al. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy // J. Int. Med. Res. – 2016; 44 (6): 1403–13.
  12. Imaoka H., Hoshino T., Takei S., et al. Interleukin-18 production and pulmonary function in COPD // Eur. Respir. J. – 2008; 31: 287–97.
  13. Hivert M., Sun Q., Shrader P. et al. Circulating IL-18 and the risk of type 2 diabetes in women // Diabetologia. – 2009; 52 (10): 2101–8.
  14. Abbas S. Comparative study of Interleukin-33 in Male with Chronic Obstructive Pulmonary Disease, Asthmatic Patients with Type 2 diabetes mellitus // Int. J. Innovat. Res. Sci., Engin. Technol. – 2013; 2 (11): 5947–54.
  15. Ziyadeh F. Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator // J. Am. Soc. Nephrol. – 2004; 15: 55–7.
  16. Oh Y.-M., Jeong B.-H., Woo S.-Y. et al. Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression // Ann. Am. Thorac. Soc. – 2015; 12 (7): 1005–12.
  17. Franssen F., O’Donnell D., Goossens G. et al. Obesity and the lung: 5. Obesity and COPD // Thorax. – 2008; 63: 1110–7.
  18. Maneechotesuwan K., Wongkajornsilp A., Adcock I. et al. Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD // CHEST. – 2015; 148 (5): 1164–76.
  19. O’Byrne P., Rennard S., Gerstein H. et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids // Respir. Med. – 2012; 106: 1487–93.